TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sexual Risk Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in acute pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participant satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: nurse satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood BHB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ghrelin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reported hunger and desire to eat
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: UDVA and CNVA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of field (DOF) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smoking-related cognitive and behavioral changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urethral angle measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of ocular vergence return to original phoria position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of AAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free fraction of quinidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AEFI reporting rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mean absolute number of all lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PHA-induced T-cell lymphoblast transformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NK cytotoxic activity against K562 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Platelet aggregation grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative bleeding volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red blood cell units received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of hemodynamic depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in St. George's Respiratory Questionnaire (SGRQ) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in exercise tolerance (ESWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Satisfaction level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean International Prostate Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximal urinary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in resting heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in blood flow in the leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximal walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in arterial oxygenation (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Resolution of acute mountain sickness symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mean change in PDFF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge regarding risks/benefits
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Value congruence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rates of remission at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total work performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean drainage of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: myocardial infarction or coronary heart disease death
Endpoint domain: Mortality/survival
Primary endpoint: Median fasting gastrin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pain score at probe manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of prescribed ACE inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Quality of Life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of major depression
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in micturition diary variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and intensity of dry mouth
Endpoint domain: Adverse events/effects
Primary endpoint: Hidradenitis Suppurativa Clinical Response score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma drug concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach C(max) (t(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative efficacy of LAIV versus TIV for matched strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75% reduction of vitiligo lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clearance of vitiligo lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PGA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scan time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in the CT examination room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient involvement in deprescribing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trunk flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type 2 Diabetes (T2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CO2 reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Likelihood of teachers employing CBPA tools
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of ROP recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: six minute walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD score scale part II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MFCS at 1 min and 3 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in partial seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bilateral middle cerebral artery blood flow velocities (CBFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dynamic CA indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcutaneous and end‐tidal CO(2) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of BSI
Endpoint domain: Adverse events/effects
Primary endpoint: Range of motion in active ankle dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of crown or tooth
Endpoint domain: Mortality/survival
Primary endpoint: Blood Pressure (BP) elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse (P) elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mental health scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: P‐tHcys levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: S‐MMA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower tri‐iodothyronine (T(3)) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Increased t(1/2) of exogenously administered TRH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Repressed TSH response to TRH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: adequate analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption via PCA
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-operative course difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global assessment of pain control as 'excellent'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: i-PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Granulocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Production of GM‐CSF, IL‐5 and IFNgamma by PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anteroposterior patellar-tilt angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: temporary pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Wound volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Energy intake inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma cholecystokinin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average platelet count (APC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of sneezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year adherence to statins
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 1-year adherence to antihypertensive regimens
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: palmar sweating control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dry hand problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compensatory sweating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in Sleep Position (SP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesion to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma cortisol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PRL response to D‐fenfluramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain associated with needle puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain associated with intramuscular infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean ASES score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of fluoroscopic shootings until guide wire insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: skin elastic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin elastic extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: maximum and average roughness values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: long-term cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of knee pain worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall perceived support availability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of new friends made
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Visceral fat area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knowledge levels about ACS symptoms and treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of persistent graft dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe infections
Endpoint domain: Adverse events/effects
Primary endpoint: serum total IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 General Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: W-BQ12 Energy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: CSF levels of tau and AD7C‐NTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EBP-Knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EBP-Personal application
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: EBP-Future use
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: mean numbers of incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean numbers of micturitions/24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major catheter-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent testosterone metabolic clearance rates (aMCR-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: rPFS (radiographic progression-free survival)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OS (overall survival)
Endpoint domain: Mortality/survival
Primary endpoint: incidence of severe TEAEs (treatment emergent adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: AOFAS Hindfoot scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear production impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear turnover impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric mucosal pH (pHi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Partial pressure of carbon dioxide (PCO2) gap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in loneliness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: reduction in social anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decline in depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Airway thickness of dilated bronchus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neutrophil in the sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MACTAR change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3/4 thrombocytopenia and neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: maximum resting anal sphincter pressure (MRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma [NO3‐] and [NO2‐]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in the time-trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of evidence-based treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Health care costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Sick leave days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Physical impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TNF‐α concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: poor survival
Endpoint domain: Mortality/survival
Primary endpoint: Excess risk of local adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Excess risk of systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Excess risk of events leading to search for medical care or interruption of work activities
Endpoint domain: Adverse events/effects
Primary endpoint: Caloric consumption post-GBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Controlled release profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivered pregnancy rates per transfer
Endpoint domain: Mortality/survival
Primary endpoint: endometrial advancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time to progression (TTP) in NSCLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of fluid retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Improvement Index (CII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive test exploring attention and visuo-spatial memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Change of Direction (COD) ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in linear speed (30-m and 10-m performance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average hopping power and jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Activities of Daily Living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean PIPP scores at 30 s post procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative renal insufficiency
Endpoint domain: Adverse events/effects
Primary endpoint: Arrhythmia
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dental hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained widespread pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in power required to reach 20°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DVR percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in thermal dose deposited to nontreatment tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high quality rates of oocytes and embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Likelihood of discharge from ED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the aLiFE intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with the online screening program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: secretion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confidence in symptom management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: confidence in communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing